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INVESTIGATING THE FUNCTION AND THERAPEUTIC POTENTIAL OF THE 
GCN5B BROMODOMAIN IN TOXOPLASMA GONDII 
 
The obligate intracellular protozoan parasite Toxoplasma gondii is a 
medically relevant pathogen that has infected a third of the world’s population. 
Toxoplasma is the causative agent of toxoplasmosis, which can have severe 
repercussions such as encephalitis and even death in immunocompromised 
patients. Current treatments for toxoplasmosis only target acute infection and can 
be toxic to patients, resulting in complications including allergy and bone marrow 
suppression. Thus, the identification of novel drug targets and therapies for 
toxoplasmosis is vital. Epigenetic modulators of lysine acetylation, including 
‘writers,’ ‘erasers,’ and ‘readers,’ have been identified as promising drug targets 
for protozoan parasites. The lysine acetyltransferase (KAT) GCN5b appears to 
be an essential gene for Toxoplasma viability. The KAT domain of GCN5b is 
essential to GCN5b function and is targetable by small molecule inhibitors. While 
the acetyltransferase activity of this gene is well-characterized, the functionality 
of its C-terminal bromodomain (BRD) remains to be understood. Bromodomains 
are readers of lysine acetylation, and recently, bromodomain inhibitors have 
shown promise in a number of human diseases, as well as in protozoan 
parasites. We hypothesized that the GCN5b bromodomain is critical for 
Toxoplasma viability. The data reported herein suggest that the GCN5b 
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bromodomain is important for tachyzoite viability and may serve as a novel 
therapeutic target in Toxoplasma. 
 
                                                                  William J. Sullivan, PhD, Chair       
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CHAPTER 1: INTRODUCTION 
 
1.1 Toxoplasma gondii is a model apicomplexan parasite 
The obligate intracellular protozoan parasite Toxoplasma gondii is a model 
organism for the apicomplexan phylum, which consists of other medically 
relevant pathogens that infect humans and animals [1]. Some of the 
apicomplexan parasites that infect humans include Plasmodium, the causative 
agent of malaria, and Cryptosporidium, the causative agent of cryptosporidiosis; 
apicomplexans that infect non-human animals include Neospora, which infects 
cattle, and Eimeria, which causes coccidiosis in poultry. The apicomplexans are 
characterized by a polarized cell structure with a complex arrangement of 
cytoskeleton and organelles at the apical end [2], including secretory organelles 
such as rhoptries and micronemes, which are important for parasite adhesion 
and invasion [3]. 
The experimental and genetic tractability of Toxoplasma make it a useful 
model organism. Toxoplasma is easily propagated in culture and has a well-
established mouse model [1]. Furthermore, due to ease in detecting Toxoplasma 
organelles microscopically, Toxoplasma has been used to study a number of 
apicomplexan biological processes including apicoplast development, roles of 
actin and mysosin in motility and cytoskeleton, and invasion of host cell by 
secretion of rhoptry contents [1].  
Toxoplasma is amenable to genetic manipulation, including stable 
transient transfection [4], epitope tagging [5], ectopic expression [6], and 
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generation of reporter genes [7]. Toxoplasma is also amenable to genetic 
disruption by allelic replacement [8] and CRISPR/Cas9 technology [9,10]. In fact, 
the first genome-wide genetic screening of an apicomplexan was performed in 
Toxoplasma, where CRISPR/Cas9 was utilized to identify essential 
apicomplexan genes [9]. Additionally, Toxoplasma has a fully sequenced 
genome (12x coverage) and a functional genomic database (ToxoDB) for 
integrated Toxoplasma data, including genomic sequence and annotation, as 
well as other information such as orthologs, single nucleotide polymorphisms, 
and proteomics data [11]. 
 
1.2 Life cycle of Toxoplasma 
Toxoplasma has the ability to infect nearly all nucleated cells in warm-
blooded animals and has been estimated to have infected about one-third of the 
world’s population [12]. Part of the success in the transmission of Toxoplasma is 
the ability of the parasite to convert between multiple, infectious forms and to infect 
via different routes [13]. Infectious stages of Toxoplasma include: tachyzoites, 
bradyzoites, and sporozoites, reviewed in [2]. Tachyzoites rapidly proliferate within 
the intermediate host and non-intestinal epithelial cells of the definitive host, the 
felid. Tachyzoites actively penetrate through host cells or are phagocytosed. Upon 
invasion, tachyzoites are surrounded by a parasitophorous vacuole, within which 
they replicate asexually by endodyogeny (formation of two daughter cells inside a 
mother cell), and then egress and invade a nearby cell. Tachyzoites can convert 
into slowly dividing, virtually quiescent bradyzoites that form tissue cysts 
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throughout the body, predominantly in neural and muscular tissues, including the 
brain, eyes, skeletal, and cardiac muscles. Bradyzoites characterize the chronic 
form of Toxoplasma infection, as they can persist throughout the life of an 
individual and are impervious to Toxoplasma treatment. Upon 
immunosuppression, bradyzoites can convert to tachyzoites [14]. 
The life cycle of Toxoplasma is reviewed in [2]. The definitive host of 
Toxoplasma, the cat (Felidae family), is the only organism in which the parasite 
can undergo the sexual stage of its life cycle. Parasites multiply within the 
intestinal epithelium of cats, initiating gamete formation. Unsporulated, 
environmentally stable oocysts (cysts containing Toxoplasma zygotes) are shed 
in the cat feces and are sporulated in the environment within a few days. The 
sporulated, infectious oocysts can contaminate food, water, and soil and infect 
intermediate hosts, such as livestock. After ingestion of infectious oocysts, 
sporozoites develop into tachyzoites, which covert to bradyzoites in tissue cysts. 
The cat can become infected via consumption of environmental oocysts or tissue 
cysts from intermediate hosts. Humans can become infected through ingestion of 
food or water contaminated with oocysts or tissue cysts in infected, undercooked 
meat. Mothers can vertically transmit Toxoplasma to the fetus through the 
placenta. Additionally, Toxoplasma can be acquired through solid organ and 
hematogenous stem cell transplants, either through reactivation of latent infection 
or de novo infection due to immunosuppression [15]. 
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1.3 Toxoplasmosis and treatments  
Toxoplasma poses a significant health risk to humans and livestock, 
necessitating the development of effective and safe drugs. Acute infection is 
characterized by rapidly proliferating tachyzoites but is often asymptomatic in 
immunocompetent hosts. The healthy immune system controls the infection 
within weeks, at which point Toxoplasma establishes a chronic, latent infection 
characterized by its conversion into bradyzoite tissue cysts [16]. As the parasite 
is not eradicated from the host, it can reactivate to cause acute, opportunistic 
infection in immunocompromised individuals, such as those infected with HIV. 
Extensive tissue damage can occur during reactivated toxoplasmosis that results 
in severe complications including ocular toxoplasmosis and Toxoplasma 
encephalitis, which is typically the leading cause of death following reactivation of 
Toxoplasma infection [17]. Additionally, Toxoplasma tachyzoites can be 
transplacentally transmitted from mother to fetus to cause congenital 
toxoplasmosis, which can result in birth defects, such as neurological and visual 
impairment and spontaneous abortion [18]. 
There is currently no treatment against chronic Toxoplasma infection 
(bradyzoite tissue cysts) [13]. The first line of therapy for acute toxoplasmosis is 
a combination of pyrimethamine and sulfadiazine, often administered with 
leucovorin to reduce cytotoxicity [19]. Pyrimethamine and sulfadiazine inhibit 
parasite replication by blocking the folate metabolic pathway, but the treatment is 
not effective against latent tissue cysts [20]. The treatment is also toxic, putting 
patients at risk of bone marrow suppression and dermatologic and 
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gastrointestinal events; discontinuation or change in this treatment regimen due 
to adverse events occurred in over 55% of studies analyzed in a systematic 
review [20]. As a result of these shortcomings, there is an urgent need for the 
identification of novel drug targets to facilitate the development of more effective 
and better-tolerated treatments for toxoplasmosis.  
 
1.4 Epigenetics and lysine acetylation 
A promising area of investigation for potential drug targets in Toxoplasma 
includes protein complexes that “read” and “write” posttranslational modifications 
(PTMs), including lysine acetylation [21]. The addition and removal of acetyl 
marks from lysine residues is mediated by lysine acetyltransferases (KATs) and 
lysine deacetylases (KDACs), respectively. In the literature, enzymes with 
acetyltransferase activity on lysine residues may also be referred to as ‘histone 
acetyltransferases’ (HATs), as histones were their initially discovered substrates. 
However, upon the discovery that acetyltransferases also have non-histones 
substrates, Allis et al. [22] called for a change in nomenclature to ‘lysine 
acetyltransferase’ (KAT).  
Acetylation of lysine on the ε-N-amino acid neutralizes the positive charge 
and allows for loosening of chromatin, which is generally linked to transcriptional 
activation [23]. Lysine acetylation has emerged as a key PTM taking place on 
hundreds of proteins throughout various compartments in the cell. Extensive 
lysine acetylation occurs in both Toxoplasma and the fellow apicomplexan 
parasite Plasmodium on proteins that function in a variety of areas including 
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metabolism, translation, chromatin biology, and stress response [24,25]. In 
addition, lysine acetylation of histones is correlated with stage-specific gene 
expression and stage conversion in Toxoplasma [26].  
 
1.5 GCN5 lysine acetyltransferases 
Conservation among organisms: 
GCN5 (general control nonderepressible-5) is a nuclear transcriptional co-
activator that is highly conserved among vertebrates, plants (Arabidopsis), 
Drosophila, yeast, humans, and protozoan parasites [27-29]. GCN5 has 
conserved functional domains, including a lysine acetyltransferase domain, 
ADA2-binding domain, and C-terminal bromodomain [27].  
 
GCN5 in yeast and humans:  
GCN5 appears to be important for transcriptional activation and stress 
response. GCN5 has conserved acetyltransferase activity on histone H3 and 
transcriptional activation of target genes in yeast and humans [30,31]. The 
acetyltransferase activity of GCN5 is required for the regulation of stress-
response genes in evolutionarily divergent yeast species [32]. In Saccharomyces 
cerevisiae, which possess a single GCN5, GCN5 is not essential for growth 
under normal conditions, but required for growth on minimal media [33]. Humans 
possess two GCN5 homologues, GCN5L2 (KAT2A) and PCAF (p300/CBP-
associated factor) (KAT2B). GCN5 (KAT2A) is required for mouse 
embryogenesis; while, human PCAF is not [34,35]. Dysregulation of PCAF has 
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been implicated in disease states including cancer, HIV infection, and 
neuroinflammation [36]. Both yeast and human GCN5 function as part of ADA2- 
and SAGA (Spt-Ada-GCN5-acetyltransferase)-containing complexes to drive 
transcriptional initiation and activation [37].  
 
GCN5 in protozoan parasites: 
Plasmodium: 
A single GCN5, with a single C-terminal bromodomain, has been identified 
in Plasmodium species. In 2004, Fan et al. [38] identified a GCN5 homologue in 
Plasmodium falciparum with conserved lysine acetyltransferase activity on 
histone H3 tails. This group found that PfGCN5 associated with PfADA2 in vitro, 
suggesting that GCN5 is involved in chromatin remodeling in Plasmodium. Rawat 
et al. [39] found that GCN5 may serve as a transcriptional regulator of stress 
responses in Plasmodium. They found that PfGCN5 binds to stress responsive 
genes and, under stress conditions, regulates the expression of genes important 
for parasite cellular homeostasis. Cui et al. [40] found enrichment of H3K9 
acetylation at putative transcriptional initiation sites corresponding to expression 
of erythrocytic stage-specific genes. Additionally, they found that curcumin, which 
appears to be an inhibitor of the PfGCN5 acetyltransferase domain [41], led to 
reduced promoter H3K9 acetylation and gene expression, suggesting that 
PfGCN5 is recruited to gene promoters to mediate histone acetylation and stage-
specific gene expression. 
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In addition to suggested roles in chromatin remodeling and transcriptional 
regulation, GCN5 may be important for malarial viability and pathogenicity 
[39,42]. Treatment of P. falciparum with a GCN5-related N-acetyltransferase 
(GNAT) family KAT inhibitor, embelin, resulted in a reduction in H3K9 acetylation 
levels around the promoters of var genes, a family of genes important for malarial 
pathogenicity, and a decrease in var gene expression. Embelin treatment also 
resulted in inhibition of Plasmodium growth at a low micromolar range [42]. A 
screen of compounds against the PfGCN5 acetyltransferase domain identified 
molecule C14 as a specific inhibitor of the PfGCN5 acetyltransferase domain. 
Treatment with C14 reduced recombinant PfGCN5 activity and H3K9 acetylation 
levels, as well as inhibited Plasmodium growth at a low nanomolar range [43]. 
Additionally, inhibition of GCN5 reverses sensitivity to artemisinin, suggesting 
that GCN5 may play a role in modulating drug resistance to artemisinins [39]. 
These data suggest that the GCN5 lysine acetyltransferase domain may serve as 
a targetable therapeutic domain in Plasmodium.  
 
Toxoplasma: 
Two GCN5 family KATs have been identified in Toxoplasma and 
designated GCN5a and GCN5b [8]. Each has a lengthy N-terminal extension, a 
KAT domain, and a single C-terminal bromodomain. The two GCN5’s in 
Toxoplasma also show conservation of acetyltransferase activity on histone H3 
(though they have different substrate specificities in vitro) and formation of ADA2 
complexes. GCN5a preferentially acetylates H3K18 [26]; however, GCN5b 
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acetylates H3K9, 14, and 18 [8]. Toxoplasma possesses two ADA2 homologues, 
ADA2-A and ADA2-B [8]. GCN5a interacts with ADA2-B [8]; however, GCN5b 
has been associated with at least two distinct protein complexes, both 
characterized by interaction with ADA2-A [44]. 
 Knockout studies indicate that GCN5a is dispensable for tachyzoite 
proliferation but required for proper stress responses [45]. Conversely, multiple 
attempts to knockout GCN5b have failed [45,6]. Wang et al. [6] previously 
observed that when a catalytically inactive form of GCN5b (GCN5bE703G) was 
ectopically expressed, it exerted a dominant negative effect, resulting in arrest of 
parasite proliferation. This supports the idea that GCN5b is essential for 
tachyzoite viability. Additionally, ChIP-chip analysis demonstrated that GCN5b is 
enriched at tachyzoite-specific genes involved in transcription, translation, and 
metabolism [6]. Jeffers et al. [46] demonstrated that the KAT inhibitor garcinol 
appears to target the KAT domain of GCN5b. Treatment of Toxoplasma with 
garcinol in vitro decreases GCN5b auto-acetylation, alters expression of genes 
linked to GCN5b control, and inhibits parasite replication [46]. These data, along 
with a recent genome-wide fitness screen reporting a mean phenotype score of   
-2.96 [9], strongly support GCN5b as an essential gene. 
 
1.6 Bromodomain proteins 
Conservation among organisms: 
The bromodomain was first identified as a structural motif in the 
Drosophila melanogaster brahma protein, a nuclear chromatin remodeling 
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protein involved in the activation of homeotic genes [47]. Since then, it has been 
determined that the bromodomain is a highly conserved domain among humans 
[48], yeast [49], and protozoan parasites [29] in proteins involved in the 
regulation of gene expression.  
In the human proteome, 61 bromodomains, encoded by 46 proteins, have 
been identified and structurally clustered into eight major phylogenetic families 
[48]. The two human GCN5 homologues (GCN5L2 and PCAF) belong to the first 
phylogenetic family of bromodomains, which also consists of genes FALZ and 
CECR2. In yeast, 14 bromodomains, encoded by 9 bromodomain-containing 
proteins, have been identified [49]. 
In protozoan parasites, bromodomains are conserved among different 
phylums, including the Euglenozoa phylum (Trypanosoma cruzi and 
Trypanosoma brucei) and the Apicomplexa phylum (Plasmodium falciparum and 
Toxoplasma gondii), reviewed in [29]. There are 12 predicted bromodomain-
containing proteins in Toxoplasma. Among them, only three have been 
characterized (histone acetyltransferases TgGCN5a, TgGCN5b, and TAF1/250). 
The P. falciparum GCN5 protein also contains a C-terminal bromodomain.  
 
Structure: 
The bromodomain is comprised of ~110 amino acids and folds into a 
conserved left-handed bundle of four helices (Z, A, B, and C) joined by two 
variable loops (ZA and BC) that form a deep hydrophobic pocket in which the 
acetyl lysine binds [50]. The amino acid residues within these variable loop 
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regions determine binding specificity of the acetyl lysine [50]. The interaction 
between the acetyl lysine and the hydrophobic pocket of the bromodomain is 
generally stabilized by hydrogen bonding between the acetyl lysine and the ZA 
and BC loops, specifically hydrogen bonding between the carbonyl group and 
amide nitrogen in the acetyl lysine and a group of conserved water molecules 
that hydrogen bond with residues within the ZA loop, as well as hydrogen 
bonding between the oxygen of the acetyl carbonyl of the acetyl lysine and an 
amide nitrogen of an asparagine within the BC loop [51].   
 
Binding Activity: 
The bromodomain structure was first reported for PCAF by nuclear 
magnetic resonance (NMR) [50]. NMR titrations of the PCAF bromodomain with 
a histone H4 peptide containing an acetylated lysine residue demonstrated that 
the bromodomain binds specifically to acetylated lysine residues [50]. 
Filippakopoulos et al. [48] assessed the binding specificity of 33 
representative human bromodomains for singly acetylated histones in vitro. This 
group observed differences in ligand binding specificities among bromodomains, 
as well as differences in electrostatic potential surrounding the acetyl-lysine 
binding sites, suggesting that bromodomains recognize markedly different 
sequences. Bromodomain binding specificities for singly acetylated histones 
were generally low; however, in the majority of bromodomains tested, binding 
specificity for acetylated histones increased in the presence of multiple 
posttranslational modifications (such as phosphorylation) on histone H3, 
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suggesting that bromodomain activity is influenced by neighboring modifications. 
 
Function: 
Human bromodomain-containing proteins have a variety of functions, 
reviewed in Table 1 of [52], including roles in: transcriptional initiation (TAF1), 
regulation (BRD4), elongation (TRIM33), activation (BRPF1), and even 
repression (BAZ2A), as well as histone acetylation (PCAF), chromatin 
remodeling (CECR2), and protein scaffolding (BRD1). The majority of these 
bromodomain-containing proteins localize exclusively to the nucleus, with some 
also localizing to the cytoplasm [52].   
 
1.7 GCN5 bromodomains 
Conservation among organisms: 
GCN5 bromodomains have relatively high conservation among species 
(Table 1) (Figure 1a).  
Table 1. Sequence identity of GCN5 bromodomains across select, 
representative species. Amino acid sequences from S. cerevisiae (Sc), 
H. sapiens (Hs), P. falciparum (Pf), and T. gondii (Tg). Amino acid 
alignment was conducted via Clustal Omega (version 1.2.4) multiple 
sequence alignment (shown in Figure 1a) and percentage sequence 
identity was determined by Clustal 2.1 analysis.  
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Function: 
In vitro and in vivo studies of the GCN5 SAGA complex in yeast elucidate 
roles for the GCN5 bromodomain in the following areas: transcriptional activation 
of GCN5 co-activators [53,54], stabilization of complexes to promoter regions 
[55], nucleosome remodeling [54], and regulation of acetyltransferase activity 
[56-58].  
Yeast reporter gene assays indicate that the GCN5 bromodomain is 
necessary for transcriptional activation of GCN5 co-activators in vivo [53,54]. In 
addition to transcriptional activation, the GCN5 bromodomain plays a role in 
complex/promoter association. The GCN5 bromodomain anchors the SAGA 
complex to acetylated promoter nucleosomes in vitro [55] and stabilizes the 
association of the Swi/Snf (Switch/Sucrose Non-Fermentable) chromatin 
remodeling ATPase complex within promoters in vivo, suggesting a role for the 
GCN5 bromodomain in nucleosome remodeling [54]. 
The GCN5 bromodomain also functions in regulating acetylation activity, 
including cooperativity of acetylation, and acetylation levels and specificity. In 
vitro nucleosome assays conducted by Li and Knaak indicate that the yeast 
SAGA complex acetylates H3 and H4 histone tails in nucleosomes in a 
cooperative fashion in vitro, where binding of the SAGA complex to one 
nucleosome increases the affinity of the complex for another, non-contiguous 
nucleosome [56,57]. SAGA-mediated cooperativity of nucleosome acetylation is 
dependent upon a functional GCN5 bromodomain [57]. Additionally, cooperative 
nucleosome acetylation of histone H3 tails requires that the SAGA complex 
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interacts with both histone H3 tails within the nucleosome, and that the histone 
tails exist in their proper orientation (cooperative acetylation does not occur when 
H3 tails are switched to H4 tail locations). These results suggest that the 
bromodomain may facilitate contact between non-contiguous nucleosomes 
through acetylated histone tail interactions [56].  
Li and Knaak [57] observed that the GCN5 bromodomain increases the 
affinity of the SAGA complex for nucleosomes that are pre-acetylated on a single 
histone H3 or H4 tail. In the presence of a single pre-acetylated H3/H4 histone 
tail, the GCN5 bromodomain facilitates cross-tail acetylation of other histone H3 
tails (without changing the site specificity of histone acetylation). Moreover, the 
GCN5 bromodomain increases turnover of H3 tail acetylation in the presence of 
a single pre-acetylated histone H4 tail within nucleosomes. 
In vitro HAT assays conducted by Cieniewicz and co-workers [58] 
demonstrated that mutation of the GCN5 bromodomain within the 
GCN5/Ada2/Ada3 subcomplex in yeast decreases levels of total histone H3 
acetylation, as well as alters site specificity of histone H3 acetylation in free and 
nucleosomal histone H3. The researchers propose a “reader/writer” model of 
GCN5 bromodomain regulation of specificity of acetylation, where GCN5 first 
acetylates histone H3 (specifically on lysine 14) and then the bromodomain 
anchors GCN5 to the acetylated residue to promote further acetylation activity 
(on H3K18). 
Taken together, these studies support a model in which the bromodomain 
of GCN5 is necessary to anchor or stabilize GCN5 to specific regions of 
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chromatin to promote further GCN5 activity, such as transcriptional activation, 
nucleosome remodeling, and acetyltransferase activity. 
 
1.8 Development of bromodomain inhibitors 
Bromodomains have been implicated in different human disease states, 
including cancer, inflammation, and viral infection. As of late 2019, there were 30 
clinical trials testing bromodomain inhibitors as therapeutics for human disorders 
[59].  
There are two classes of bromodomain inhibitors: non-acetyl-lysine-
competitive mimetics (e.g. ischemin) and acetyl-lysine-competitive mimetics (e.g. 
JQ1 and I-BET 151) [60]. The former class engages within the acetyl lysine 
binding pocket of the bromodomain but does not form canonical hydrogen 
bonding with a conserved asparagine. This class of inhibitor functions through 
steric inhibition of acetyl lysine binding. The latter class is the most common type 
developed and directly engages with the acetyl lysine binding pocket through 
hydrogen bonding with a conserved asparagine, thereby, competitively inhibiting 
binding of acetylated lysines to the bromodomain. 
In addition to bromodomain inhibitors showing therapeutic promise for 
human disease, a number of bromodomain inhibitors have been reported to have 
inhibitory activity against Toxoplasma and other protozoan pathogens, such 
as Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi  [29,61-
64]. 
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1.9 GCN5 bromodomain-specific inhibitors 
A druggability assessment reported in [65] estimates that the 
bromodomains of human GCN5L2 and PCAF are highly druggable. Currently, 
there are two available PCAF/GCN5-specific, acetyl-lysine-competitive 
bromodomain inhibitors, both of which were reported in 2017.  
Humphreys et al. [66] identified the inhibitor GSK4027, which displays 
high potency, selectivity, and cellular activity against PCAF/GCN5 
bromodomains. Moustakim et al. [36] also reported a PCAF/GCN5-specific 
inhibitor, L-Moses (also known as L-45). At the time the work of this thesis was 
conducted, GSK4027 was not commercially available; thus, L-Moses was the 
PCAF/GCN5-specific bromodomain inhibitor that was studied. L-Moses is a 
triazolopthalazine-based chemical inhibitor that demonstrates potency (KD 126 
nM for human PCAF BRD, KD 550 nM for human GCN5 BRD, and KD 280 nM for 
Plasmodium GCN5 BRD by isothermal titration calorimetry), selectivity (>4,500-
fold selective over BRD4 by differential scanning fluorimetry), and cellular activity 
against PCAF and GCN5 bromodomains, capable of displacing their binding to 
histone H3.3 in cultured HEK-293 cells (by Nanobret assay). Moustakim and 
colleagues reported the crystal structure of the Plasmodium GCN5 bromodomain 
(PDB identification 5tpx) complexed to L-Moses, which demonstrates that L-
Moses fits within the acetyl lysine binding pocket of the PfGCN5 bromodomain. 
Furthermore, L-Moses displays in vitro stability in human and mouse liver 
microsomes, as well as good in vitro solubility and permeability. Moustakim et al. 
found no observable cytotoxicity after 24 hours of 10 μM L-Moses treatment of 
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primary peripheral blood mononuclear cells. These data suggest that L-Moses 
may be used in in vivo studies. 
 
1.10 Hypothesis and aims  
GCN5b appears to be an essential gene in Toxoplasma that contributes to 
tachyzoite viability. The lysine acetyltransferase activity of GCN5b is well-
characterized; nonetheless, the function of the C-terminal bromodomain is not. 
GCN5 bromodomains in yeast and humans have implicated roles in GCN5 
function, including stabilizing GCN5 to promoters, transcriptional activation of 
GCN5 co-activators, and regulating GCN5 acetyltransferase activity. Additionally, 
two PCAF/GCN5-specific bromodomain inhibitors, GSK4027 and L-Moses, have 
been reported to be potent, selective, and active against PCAF/GCN5 
bromodomains. This work will focus on the inhibitor L-Moses. The crystal 
structure of L-Moses complexed with the GCN5 bromodomain from Plasmodium 
demonstrates that L-Moses fits within the acetyl lysine binding pocket of the 
PfGCN5 bromodomain. Thus, genetic and pharmacological approaches can 
be used to address the importance of the GCN5b bromodomain in 
Toxoplasma. We hypothesize that the GCN5b bromodomain is critical for 
Toxoplasma viability. To address this hypothesis, we pursued two specific 
aims: 
Aim 1: Assess the importance of the GCN5b bromodomain in Toxoplasma 
gondii viability.  
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Aim 2: Determine if the TgGCN5b bromodomain is a targetable element 
and, if so, the effects on the parasite of targeting this domain. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Chemicals 
 Shield (CheminPharma) was prepared in absolute ethanol. L-Moses 
dihydrochloride was purchased from Tocris (catalog no 6251) and prepared in 
DMSO. Chemicals were stored at -20C. 
 
2.2 Host cell and parasite culture 
 Primary human foreskin fibroblast (HFF) cells (ATCC) were cultured in 
Dulbecco's modified Eagle's medium (DMEM; Corning), without 
antibiotic/antimycotic, supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Gibco/Invitrogen). Toxoplasma gondii Type I RH strain parasites 
were propagated in confluent monolayers of HFF cells and cultured in DMEM, 
without antibiotic/antimycotic, supplemented with 1% heat-inactivated FBS as 
previously described [67]. Host cell and parasite cultures were maintained at 37 
°C with 5% CO2 in a humidified incubator. Plasmid DNA was transfected into 
RHΔHX parasites by electroporation and selected in 20 μM chloramphenicol; 
individual clones were isolated by limiting dilution in 96-well plates as previously 
described [67]. For assays involving Shield-based regulation, the designated 
parasites were cultured with vehicle (100% EtOH) or Shield (50 or 200 nM) for 48 
h. 
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2.3 Plasmid construction 
 To construct an expression plasmid to generate recombinant GCN5b 
bromodomain (BRD) protein in E. coli, a region of TgGCN5b (amino acids 877-
986 of TGGT1_243440 from ToxoDB) encoding the BRD (amino acids 888-985) 
was amplified by PCR from a previously described plasmid [6] using the following 
primers which include 15bp ends that are complementary to the target site in the 
pGEX-4T1 plasmid: sense primer (5′-
TGGATCCCCGGAATTCCAGATTCCAGGTCTTCTGCAGTG) and anti-sense 
primer (5′- GTCGACCCGGGAATTCCAGTTGCTTCTGCTGCTG). The TgGCN5b 
BRD sequence was inserted into the pGEX-4T1 vector at the EcoRI site (939) 
using the InFusion cloning system (Takara), for expression of TgGCN5b BRD 
protein fused to an N-terminal GST tag. To generate a fusion protein that 
expresses a mutant TgGCN5b BRD, tandem alanine substitutions 
(Y963A/N964A/Y970A) were created using the Q5 site-directed mutagenesis kit 
(NEB; E0554S) with the following primers: sense primer (5′- 
CAAACGATTGCTTACAAATACGCGAACGAG) and anti-sense primer (5′- 
CTGGTGGGCGGCCTGCCGACAGTTCTTGAAC). To generate a plasmid for 
inducible ectopic expression of GCN5b with a mutated bromodomain 
(Y963A/N964A/Y970A) in Toxoplasma, the ptubXFLAG::CAT plasmid encoding 
full-length GCN5b with N-terminal destabilization (dd) and HA tags previously 
described in Wang et al. [6] was subjected to Q5 site-directed mutagenesis using 
the same Q5 primers as listed above. The wild-type and mutant 
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ptubXFLAG::CAT plasmids were linearized with NotI before transfection into 
parasites. 
 
2.4 Purification of GCN5b bromodomain protein 
 GCN5b BRD wild-type and mutant pGEX-4T1 plasmids were transformed 
into BL21 (DE3) competent E. coli cells, which were grown to an OD600 of 0.6–
0.8 and incubated with 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 
15 to 18 h at 16 °C to induce protein expression. IPTG-induced bacteria were 
centrifuged at 20,000 rpm for 25 min at 4 °C and bacterial pellets were incubated 
with 20 mL of lysis buffer (50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5% glycerol 
(v/v), 1% Triton X-100 (v/v), 1 mM DTT, lysozyme from chicken egg white (300 
μg/mL) (Sigma Aldrich; L6876), and an EDTA-free protease inhibitor cocktail 
tablet (Sigma Aldrich; 11873580001)) for 1 h at 4 °C, following which 250 units of 
benzonase nuclease (Novagen; 2894174) and 1 mM MgCl2 were added and 
bacteria were incubated for an additional 30 min at 4 °C. The lysed bacteria were 
centrifuged at 20,000 rpm for 25 min at 4 °C and the soluble protein was purified 
and concentrated (with a 30 kDa MWCO concentrator) using the Amicon Pro 
Affinity Concentration Kit for GST fusion proteins (Millipore, ACK5030GS). 
 
2.5 In vitro binding assays 
 In vitro binding assays were conducted to assess recombinant GST-
tagged GCN5b BRD (amino acids 888-985) binding to acetylated histone H4 
peptide in a similar manner as described in [68] with minor modifications. First, 
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biotinylated histone peptides H4 (corresponding to residues 1-21 of human 
histone H4) (Epigentek, R-1007) and tetra-acetylated H4 (K5/8/12/16) 
(corresponding to residues 1-18 of human histone H4) (Epigentek, R-1008) were 
linked to streptavidin magnetic beads (NEB). To link histone peptides and 
streptavidin beads, 625 μL of streptavidin bead slurry was washed twice in 150 
mM salt solution (150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.1% Triton X-100, 
10% glycerol, 1 mM DTT) using a magnetic stand, and then resuspended in 625 
μL of 150 mM salt solution. 100 μL of histone peptide (100 μM) was added to the 
bead slurry and incubated for 15 to 18 h at 4°C. Histone peptide-linked 
streptavidin beads were washed three times in 150 mM salt solution to remove 
unbound peptide and resuspended in 625 μL of 150 mM salt solution with 0.8% 
sodium azide. Bead samples were stored at 4°C. Beads linked to unmodified H4 
peptide, as well as streptavidin beads alone, were used as negative controls in 
binding/inhibition assays. 10 μL samples of histone-linked beads and control 
bead samples were washed once with 150 mM salt solution and resuspended in 
250 μL150 mM salt solution for binding assays or 150 mM salt solution 
supplemented with vehicle or inhibitor for inhibitor assays. 1 μg BRD protein was 
added to the beads and samples were incubated for 15 to 18 h at 4°C. Beads 
were then washed five times with a 500 mM salt solution (500 mM NaCl, 50 mM 
Tris-HCl (pH 7.5), 0.1% Triton X-100, 10% glycerol, 1 mM DTT) for a total of 1 h 
at 4°C. Magnetic beads were boiled in 4X SDS loading buffer (40% glycerol, 240 
mM Tris/HCl pH 6.8, 8% SDS, 0.04% bromophenol blue, 5% beta-
mercaptoethanol) for 10 min at 95°C to elute bound bromodomain protein. Beads 
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were magnetically separated from the boiled samples and the supernatant was 
run on an SDS page gel. GST-tagged BRD protein was detected by western blot 
analysis. 
 
2.6 Western blot analyses 
 Protein samples were run on denaturing 4–12% Tris-acetate 
polyacrylamide gradient gels (Invitrogen). GST-tagged fusion proteins were 
probed with anti-GST rabbit polyclonal antibody (1:2000; Sigma, G7781). HA-
tagged fusion proteins were probed with anti-HA rat monoclonal antibody 
(1:2000; Roche #11867423001). The major surface antigen p30 was probed with 
Toxoplasma P30 mouse monoclonal antibody (1:1000; Genway GWB-44A329). 
Anti-rabbit, anti-rat, or anti-mouse antibodies conjugated with horseradish 
peroxidase (1:5000; GE Healthcare) were used as secondary antibodies. Blots 
were visualized by electrochemiluminescence using the Chemiluminescence 
Western Blot Substrate (Pierce) and imaged by FluorChem E machine 
(ProteinSimple). 
 
2.7 Immunofluorescence assays 
 Localization of proteins in Toxoplasma was determined by 
immunofluorescence assay (IFA) as previously described [6]. HFFs were grown 
to confluence on coverslips in a 12-well plate and inoculated with freshly lysed 
parasites. 18 h post-infection, medium was aspirated and coverslips were fixed 
with 4% paraformaldehyde in PBS for 10 min, washed with PBS, and then 
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permeabilized with 0.2% Triton X-100 in 3% BSA-PBS for 15 min. Plates were 
incubated with anti-HA rat monoclonal antibody (1:2000; Roche, #11867423001) 
for 2 h at room temperature, washed with PBS 3 × 5 minutes, and incubated with 
anti-rat Alexa Fluor 488 antibody (1:2000; Invitrogen, A-11006) and 4′,6-
diamidino-2-phenylindole (DAPI) (1:1000) for 1 h at room temperature. Samples 
were washed once more with PBS three times for 5 min each and visualized 
using a Nikon Eclipse 80i microscope. 
 
2.8 GCN5 bromodomain protein alignment 
Amino acid sequences utilized for protein alignment of GCN5 
bromodomains are as follows: Saccharomyces cerevisiae (Sc) GCN5 (Uniprot 
entry Q03330) (aa 344-414); Homo sapiens (Hs) GCN5L2 (Uniprot entry 
Q92830) (aa 732-831); Homo sapiens (Hs) PCAF (Uniprot Entry Q92831) (aa 
727-826); Plasmodium falciparum (Pf) GCN5 (PlasmoDB entry PF3D7_0823300) 
(aa 1352-1461); Toxoplasma gondii (Tg) GCN5a (ToxoDB entry TGGT1_254555-
t26_1) (aa 1109-1183); Toxoplasma gondii (Tg) GCN5b (ToxoDB entry 
TGGT1_243440-t26_1) (aa 888-985). Amino acid alignment was conducted via 
Clustal Omega (version 1.2.4) multiple sequence alignment [69] and percentage 
sequence identity was determined by Clustal 2.1 analysis. 
 
2.9 Modeling of TgGCN5b bromodomain 
 The predicted 3D structure of the Toxoplasma GCN5b BRD (amino acids 
877-986) was obtained via I-Tasser using unbiased settings [70-72] and 
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visualized with UCSF Chimera [73]. The UCSF matchmaker function was used to 
superimpose BRD structures. 
 
2.10 Parasite growth assays 
 For all growth assays, confluent HFF monolayers were inoculated with 
freshly harvested intracellular parasites that were scraped, syringe-lysed with a 
25-gauge needle, and counted by hemocytometer. 
 Plaque assays were used to measure parasite viability [67]. 500 parasites 
were used to inoculate HFF monolayers in a 12-well plate. Parasite lines were 
added in technical triplicate within each plate. After two hours of invasion, 
uninvaded parasites were aspirated, wells were washed twice with medium, and 
fresh medium supplemented with vehicle or drug was added. Plates were left to 
incubate undisturbed for five to seven days and then fixed with 100% ice-cold 
methanol and stained with crystal violet for visualization of plaques. Plates were 
imaged by FluorChem E machine (ProteinSimple) and host cell lysis was 
calculated using ImageJ analysis [74]. Average percentages of host cell area 
lysed were compared between parasite lines by One-way ANOVA with Dunnett's 
multiple comparisons post-hoc. 
 The IC50 of L-Moses was determined by reporter assay established by 
McFadden et al. [7] with the modifications reported in Varberg et al. [75]. 100 
RHβ1 parasites stably expressing bacterial β-galactosidase were added to each 
well of a black 96-well plate. After 2 h of invasion, wells were washed twice with 
DMEM lacking phenol red (Thermofisher Scientific), and phenol red-free DMEM 
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supplemented with vehicle or drug was added. Drug was serially diluted across 
the plate by multichannel pipette. The IC50 of pyrimethamine has been previously 
established by β-galactosidase assay and thus was used as a control [7]. After 
four days of incubation, 100 μM of the β-galactosidase substrate 
chlorophenolred-β-D-galactopyranoside (CPRG) (Sigma, #10884308001) was 
added to each well. 24 h later, β-galactosidase activity was measured by reading 
absorbance at 570 nm (excitation) and 630 nm (emission) with the Synergy H1 
Plate Reader (Biotek). Assays were conducted in technical triplicate and average 
absorbance values obtained from three biological replicates were normalized to 
wells containing uninfected host cells (maximum inhibition) and infected host 
cells treated with vehicle (DMSO) (minimum inhibition). Absorbance values were 
plotted and the IC50 was calculated by non-linear regression-variable slope (4 
parameters). 
 Parasite replication was measured by doubling assay [76]. Briefly, 1X105 
parasites were added to HFF monolayers in a 6-well plate. After 2 h of invasion, 
wells were washed twice with medium and fresh medium supplemented with 
vehicle or drug was added. Plates were fixed with 100% ice-cold methanol and 
stained with Hema 3 solutions I and II (Fisher, 23-122937/23-122952) at 24 and 
36 h post-infection to visualize parasites and vacuoles. The number of parasites 
was counted in 150 random vacuoles for three biological replicates and the 
average percent of vacuoles containing indicated numbers of parasites between 
parasite lines at designated drug concentrations were compared by two-way 
ANOVA with Tukey's multiple comparisons post-hoc. 
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2.11 Host cell cytotoxicity assay 
 To determine the effect of L-Moses on HFF cell metabolism, a CellTiter 
96® AQueous One Solution Cell Proliferation Assay (Promega; G3582) was 
conducted [77]. This colorimetric assay measures the reduction of the MTS 
tetrazolium compound to a formazan dye mediated by NAD(P)H-dependent 
dehydrogenase enzymes. Phenol red-free medium supplemented with vehicle 
(DMSO) or drug was added to confluent HFF cells in a black 96-well plate and 
serially diluted across the plate by multichannel pipette. Cells treated with 1% 
SDS were used as a positive control for inhibition of cell metabolic activity. 
CellTiter 96® AQueous One Solution Reagent was added to each well and 
incubated for four hours. The formation of formazan dye was quantified by 
measuring absorbance at 490 nm using the Synergy H1 Plate Reader (Biotek). 
Assays were performed in technical triplicate and the absorbance values from 
four biological replicates were averaged, the absorbance of the media alone (no 
cells) was subtracted, and absorbance from treated cells were normalized to 
absorbance from cells treated with vehicle. 
 
2.12 Statistical analyses 
 All statistical analyses were conducted using GraphPad Prism version 
8.3.0 for Windows, GraphPad Software, La Jolla California USA, 
http://www.graphpad.com. 
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CHAPTER 3: RESULTS 
 
Aim 1: Assess the importance of the GCN5b bromodomain in Toxoplasma 
gondii viability 
 
3.1 Alanine substitutions render the TgGCN5b bromodomain non-
functional in vitro  
 To assess the importance of the TgGCN5b bromodomain in parasite 
viability, we first sought to express GCN5b with a non-functional bromodomain, 
characterized by an inability to recognize and bind to acetylated lysine residues. 
Firstly, we validated the importance of three conserved amino acids within the 
GCN5 bromodomain, two conserved tyrosines (Y) and an internal asparagine 
(N): corresponding to Y963/N964/Y970 in Toxoplasma GCN5b (Figure 1A). 
These amino acid residues line the acetyl-lysine binding pocket formed between 
the ZA and BC loops of the bromodomain (Figure 1B) and are critical for the 
recognition of acetylated lysine residues in S. cerevisiae [51,58,78], H. sapiens 
[50,79], and P. falciparum [36].  
 To validate the importance of Y963/N964/Y970 residues in the GCN5b 
bromodomain of Toxoplasma, we expressed a recombinant, GST-tagged wild-
type (WT) and mutant (Y963A/N964A/Y970A) form of the GCN5b bromodomain 
(amino acids 877-986) in E. coli (Figure 1C) for use in an in vitro histone peptide-
binding assay, similar to [68]. It has been demonstrated that the human and 
yeast PCAF/GCN5 bromodomains bind to acetylated lysine residues on histone 
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H4, including lysines 5,8,12, and 16 [reviewed in 52]. In our assay, biotinylated 
histone H4 peptide (tetra-acetylated at lysines 5/8/12/16) was linked to 
streptavidin beads and incubated with recombinant, GST-tagged bromodomain 
protein. Streptavidin beads alone and unacetylated histone H4 peptide were 
utilized as negative controls for bromodomain binding. The interaction between 
bromodomain protein and histone peptide was captured by probing with anti-GST 
antibody. WT GCN5b bromodomain protein bound to acetylated histone H4 
peptide; however, the mutant form of the GCN5b bromodomain protein was 
unable to bind to acetylated H4 (Figure 1D). 
 
 
 
 
A. 
B. C. D. 
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Figure 1. Alanine mutations render the TgGCN5b bromodomain 
non-functional in vitro.  (A) Alignment of amino acid sequences from 
GCN5 bromodomains in Saccharomyces cerevisiae (Sc), Homo 
sapiens (Hs), Plasmodium falciparum (Pf), and Toxoplasma gondii 
(Tg). Highlighted amino acids are conserved among species. Red 
asterisks denote amino acids that were mutated to alanine in this 
study. (B) Predicted structure of Toxoplasma GCN5b bromodomain 
using I-Tasser. Amino acids that underwent alanine substitution are 
indicated. (C) Silver stain of recombinant, GST-tagged wild-type and 
mutant GCN5b bromodomain (BRD) proteins purified from E. coli. (D) 
BRD binding assay to monitor wild-type and mutant GCN5b BRD 
association with histone H4 (unmodified or acetylated, Ac), probed 
with anti-GST. 
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3.2 The bromodomain of GCN5b is important for parasite fitness  
 Following confirmation that the acetyl lysine binding activity of the GCN5b 
bromodomain can be ablated in vitro by alanine substitution at Y963/N964/Y970, 
a dominant-negative strategy, similar to that of [6], was employed. GCN5b was 
ectopically expressed with and without mutations at these critical residues, to 
determine the effect of a non-functional bromodomain on parasite viability. The 
premise of this approach is that the ectopic copy of GCN5b with mutations in the 
bromodomain will attenuate the function of the endogenous GCN5b 
bromodomain through competition for interactions with proteins and/or chromatin 
important for forming distinct GCN5 complexes, described in [44]. Using this 
dominant-negative approach, clonal transgenic parasites in type I RH strain that 
express full-length GCN5b, with or without mutations (Y963A/N964A/Y970A) in 
the bromodomain were generated. Both WT and mutant GCN5b were fused to 
an N-terminal destabilization domain (dd) and HA epitope tag, denoted as 
ddHAGCN5b or ddHAGCN5bMutBRD. The dd tag sends the fusion protein to the 
proteasome for degradation unless it is blocked by including the ligand Shield in 
the culture media [80]. Expression of ectopic ddHAGCN5b or ddHAGCN5bMutBRD was 
controllable by Shield, as assessed by immunofluorescence assay (IFA) and 
western blotting for the HA tag (Figure 2A-B). Importantly, neither the 
bromodomain mutations nor the dd disrupt nuclear localization of GCN5b (Figure 
2B).  
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Figure 2. Inducible expression of ddHAGCN5b and ddHAGCN5bMutBRD 
RHΔHX parasites via Shield regulation. (A and B) ddHAGCN5b and 
ddHAGCN5b
MutBRD 
parasites after 48 hours of incubation with vehicle or Shield. 
(A) Immunofluorescence assays to monitor expression of ddHAGCN5b and 
ddHAGCN5b
MutBRD
 by Shield. Blue indicates DAPI stain and red anti-HA stain. 
Scale bar represents 2 μm. (B) Western blot to monitor expression of 
ddHAGCN5b and ddHAGCN5b
MutBRD
 by Shield. Numeric values represent the 
band densities of Shield-treated parasites relative to vehicle-treated 
parasites, normalized to the loading control (Toxoplasma p30).  
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 Standard plaque assays with the ddHAGCN5b, ddHAGCN5bMutBRD, and 
parental (RHHX) parasites were performed and parasite growth was assessed 
by measurement of relative area of host cell lysis. Ectopic expression of 
ddHAGCN5b had no effect on parasite proliferation compared to the parental line, 
as found previously in [6]. Conversely, expression of ddHAGCN5bMutBRD resulted in 
~35% decreased lysis of the host cell monolayer (Figure 3), suggesting that a 
functional GCN5b bromodomain is important for parasite viability. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Ectopic expression of a mutated GCN5b bromodomain arrests 
parasite proliferation. Quantification of host cell area lysed in ddHAGCN5b 
and ddHAGCN5b
MutBRD 
parasites treated with 200 nM Shield relative to parental 
(RHΔHX) parasites treated with vehicle from three independent plaque assays 
performed in technical triplicate. Error bars represent standard deviation. *, 
P<0.05 by One-way ANOVA with Dunnett‘s multiple comparisons post-hoc.  
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Aim 2: Determine if the TgGCN5b bromodomain is a targetable 
element and, if so, the effects on the parasite of targeting this domain 
 
3.3 L-Moses inhibits GCN5b bromodomain binding activity in vitro 
 To determine if the GCN5b bromodomain in Toxoplasma is a targetable 
element, the ability of the chemical inhibitor L-Moses to interfere with GCN5b 
bromodomain binding to acetylated lysine residues was tested. Moustakim and 
colleagues [36] identified the PCAF/GCN5-specific bromodomain inhibitor L-
Moses and found that it was active in HEK-293 cells against the PCAF 
bromodomain. Moreover, this group reported the co-crystallization structure of 
the GCN5 bromodomain from the apicomplexan Plasmodium falciparum 
complexed with L-Moses (PDB identification 5tpx), which illustrates that L-Moses 
binds within the acetyl-lysine binding pocket of the PfGCN5 bromodomain. 
 The program I-Tasser [70-72] was utilized to generate a predicted model 
of the GCN5b bromodomain from Toxoplasma and the superimposition of this 
predicted model with the co-crystallization structure of the PfGCN5 bromodomain 
complexed with L-Moses was generated using UCSF Chimera software [73]. The 
superimposed model demonstrates that the acetyl-lysine binding pocket of the 
TgGCN5b bromodomain shares a similar structure to that of the PfGCN5 
bromodomain (Figure 4). Moreover, the amino acid residues within the 
Plasmodium GCN5 bromodomain that interact with L-Moses [36] are conserved 
in the Toxoplasma GCN5b bromodomain. Notably, two of the amino acids in the 
PfGCN5 bromodomain that interact with L-Moses include residues (Y1442 and 
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N1436, which correspond to Y970 and N964 in Toxoplasma, respectively) that 
were mutated to alanine for aim 1 of this study, further supporting the critical role 
of these residues in the function of the Toxoplasma GCN5b bromodomain. 
 
 
 
 
Figure 4. Modeling of PfGCN5 bromodomain complexed with L-Moses and 
the predicted TgGCN5b bromodomain structure. Predicted model of 
TgGCN5b bromodomain (blue) superimposed with the PfGCN5 bromodomain 
(grey) bound to L-Moses (green) (PDB identification of PfGCN5 complexed to L-
Moses is 5tpx) using Chimera Matchmaker. Purple residues are those in P. 
falciparum that interact with L-Moses. Orange text represents the corresponding 
residues in Toxoplasma. Red dots represent water molecules.  
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Due to the similar structure and conserved critical residues between the 
Plasmodium GCN5 bromodomain and Toxoplasma GCN5b bromodomain, it was 
hypothesized that L-Moses may target the Toxoplasma GCN5b bromodomain. 
Therefore, the histone peptide binding assay and recombinant, GST-tagged WT 
GCN5b bromodomain protein from aim 1 were utilized to test whether L-Moses 
can inhibit GCN5b bromodomain binding to acetylated histone H4 K5/8/12/16 in 
vitro. Results show that L-Moses, and not the vehicle (DMSO), inhibits GCN5b 
bromodomain binding to acetylated histone H4 in a dose-dependent manner 
(Figure 5), suggesting that the activity of the Toxoplasma GCN5b bromodomain 
can be disrupted by L-Moses.    
 
 
 
 
Figure 5. Treatment with L-Moses inhibits TgGCN5b bromodomain 
binding activity in vitro. BRD binding assay. Western blot was probed with 
anti-GST to display recombinant, GST-tagged GCN5b bromodomain binding 
to acetylated H4 (AcH4) in the presence of vehicle or L-Moses. 
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3.4. L-Moses inhibits Toxoplasma replication 
Following confirmation that L-Moses inhibits GCN5b bromodomain binding 
activity in vitro, the effect of L-Moses on tachyzoite proliferation in HFF host cells 
was assessed. A reporter gene assay, established by [7], was utilized; whereby, 
RH strain parasites engineered to express bacterial β-galactosidase were 
cultured in increasing concentrations of drug, in a similar manner as [75]. Results 
show that L-Moses inhibits parasite proliferation at an IC50 of ~0.6 M (Figure 
6A). According to an MTS viability assay [77] measuring metabolic activity of 
HFF cells, L-Moses has >150-fold selectivity for the parasite over the host cell, as 
L-Moses is not cytotoxic to host cells at concentrations up to 100 μM (Figure 6B). 
Additionally, no overt effects on host cell morphology were observed after four 
days of HFF incubation with 100 μM L-Moses. 
The next question addressed was whether the GCN5b bromodomain is a 
target of L-Moses in the parasite. It was reasoned that if GCN5b were a target, 
overexpression of GCN5b would confer some resistance to L-Moses. Thus, 
parasite growth assays using a previously generated clonal parasite line that 
constitutively overexpresses full-length GCN5b (HAGCN5b), described in [81], 
were conducted in the presence of drug. Plaque assay indicates that L-Moses 
decreases viability of parasites overexpressing GCN5b to a lesser degree than 
parental (RHHX) parasites, as demonstrated by smaller and fewer plaques 
(Figure 6C).  
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Figure 6. Treatment with L-Moses inhibits Toxoplasma proliferation. (A) 
Proliferation assay showing average percent inhibition of the reporter activity of 
RH parasites constitutively expressing β-galactosidase in the presence of 
increasing concentrations of L-Moses. Shown are data from three independent 
experiments performed in technical triplicate. (B) MTS assay showing average 
percentage of host cell viability in L-Moses-treated cells relative to vehicle-
treated cells. Data from four independent experiments performed in technical 
triplicate are shown. (C) Plaque assay showing fitness of parental parasites 
versus parasites over-expressing GCN5b, treated with vehicle or L-Moses. 
Images under the wells are magnified areas of the regions outlined by the 
yellow circle. This is representative of three independent trials showing similar 
results.  
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Furthermore, a doubling assay shows that L-Moses decreases parasite 
replication in the parental line compared to the GCN5b overexpression line at 36 
hours post-infection (Figure 7).  
 
 
 
 
 
 
 
Figure 7. Treatment with L-Moses inhibits Toxoplasma replication. 
Doubling assay showing the average percent of vacuoles containing the 
indicated number of parasites per vacuole.150 random vacuoles were 
counted from three independent experiments. *, P<0.05, **, P<0.01, and ***, 
P<0.001 between parasite lines at the given concentration of drug by Two-
way ANOVA with Tukey’s multiple comparisons post-hoc. For all graphs, error 
bars represent standard deviation. 
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
 
Aim 1: Assess the importance of the GCN5b bromodomain in Toxoplasma 
gondii viability 
Results for aim 1 show that recombinant expression of GCN5b with 
alanine substitutions at conserved residues (Y963/N964/Y970) that line the 
acetyl-lysine pocket of the bromodomain ablates bromodomain binding to tetra-
acetylated histone H4 peptide in vitro. Furthermore, ectopic expression of 
GCN5b with these same bromodomain mutations results in a reduction in 
parasite proliferation, as determined by plaque assay. These data suggest that 
the GCN5b bromodomain is important for parasite viability.  
The molecular roles of the GCN5b bromodomain in Toxoplasma and 
GCN5b function are not known at this time. Perhaps, the TgGCN5b 
bromodomain plays a similar role to the reported functions of GCN5 
bromodomains in yeast and humans, including roles in anchoring complexes at 
promoter regions  [55], transcriptional activation of GCN5 co-activators [53,54], 
nucleosome remodeling [54], coordinating cooperative acetylation [57], and 
regulating acetyltransferase activity [56-58]. Additionally, the literature suggests 
that the GCN5b bromodomain may play a role in stabilizing GCN5b protein-
protein interactions, such as those with AP2 transcription factors [6,44], through 
its acetyl lysine binding activity [24].  
Immunoprecipitation studies followed by mass spectrometry demonstrate 
that GCN5 interacts with AP2 putative transcription factors in Toxoplasma [6,44]. 
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Harris et al. [44] found that GCN5b is associated with at least two distinct protein 
complexes, characterized by interaction with different AP2 factors, during normal 
and alkaline pH stress conditions. Under normal pH conditions, GCN5b 
associates with AP2X-8 and AP2IX-7, which are subject to lysine acetylation [6], 
as well as AP2XII-4. Under both normal and alkaline stress conditions, GCN5b 
associates with ADA2-A, which is subject to lysine acetylation, as well as two 
PHD-finger domain-containing proteins. PHD domains have been reported as  
‘readers’ of lysine acetylation and methylation, particularly on histone H3 [82]. 
These domains are the most common chromatin module with which 
bromodomains associate [83], such as with the tandem PHD-finger-
bromodomain-containing human co-repressor KRAB-associated protein 1 
(KAP1), where the PHD domain and TIF1β BRD function together as a SUMO 
E3 ligase to promote transcriptional gene silencing [84]. The presence of multiple 
acetylated proteins, as well as PHD-domain-containing proteins, in the GCN5b 
complex suggests that the bromodomain may play a role in stabilizing these 
protein interactions through its acetyl lysine binding activity. The demonstration 
that TgGCN5b acetylates histone H3 [8], and that yeast and human GCN5 
bromodomains have been shown to interact with acetylated histone H3 residues 
[52], lends support to the idea that the bromodomain is important for stabilizing 
GCN5 KAT-mediated interactions. Additionally, Toenhake and colleagues [85] 
found that an AP2 factor recruits a bromodomain-containing protein to target 
gene promoters in P. falciparum. Thus, the GCN5b bromodomain may play a role 
in stabilizing GCN5 interaction, through its acetyl-lysine binding activity, with AP2 
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factors, among other proteins, to drive stage-specific gene expression in 
apicomplexan parasites.  
Future studies to investigate the molecular functions of the GCN5b 
bromodomain in Toxoplasma could utilize the parasite lines generated in this 
work, as well as parasites with GCN5b bromodomain disruption introduced by a 
different methodology, such as endogenous mutation [5] or disruption by allelic 
replacement [8] or CRISPR/Cas9 technology [9,10]. However, TgGCN5b 
bromodomain disruption via these methods may not be possible if the 
bromodomain is an essential domain in GCN5b. An alternative approach could 
be to utilize the auxin-inducible degron (AID) system for conditional protein 
depletion [86]; whereby, endogenous GCN5b could be tagged with AID and then 
conditionally depleted by the addition of auxin. Complementation clones with 
various mutations in the GCN5b bromodomain could then be introduced in the 
presence of auxin. Studies using the parasite lines described above could assess 
Toxoplasma viability in the presence of GCN5b bromodomain disruption. 
Moreover, studies could investigate the role of the bromodomain in GCN5b-
mediated acetyltransferase activity, gene expression, and GCN5b interaction 
with proteins and chromatin, as reported in [6], by western blotting, qPCR, 
immunoprecipitation, and chIP analyses, respectively. Studies could also 
investigate the role of the bromodomain in the Toxoplasma lytic cycle, such as in 
replication [76], invasion [87], and egress [88]. Understanding the roles of the 
GCN5b bromodomain in Toxoplasma will confer better understanding of the role 
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of the essential gene GCN5b, as well as provide insight into mechanisms and 
implications of targeting the bromodomain therapeutically.  
 
Aim 2: Determine if the TgGCN5b bromodomain is a targetable element 
and, if so, the effects on the parasite of targeting this domain 
Results for aim 2 show that the PCAF/GCN5 bromodomain inhibitor L-
Moses inhibits recombinant GCN5b bromodomain binding to tetra-acetylated 
histone H4 peptide in vitro. Furthermore, L-Moses has anti-parasitic effects on 
tachyzoites at concentrations that do not appear to be cytotoxic to host cells. 
Treatment with L-Moses inhibits parasite proliferation, as evidenced by β-
galactosidase assay (IC50 ~0.6 μM) and plaque assay. Parasites overexpressing 
GCN5b are less susceptible to L-Moses compared to parental parasites, as 
evidenced by plaque and doubling assay. These data support a model in which 
GCN5b is a major target of L-Moses in the parasite. Nonetheless, this work does 
not rule out additional mechanisms of action or targets of L-Moses.  
It is worth noting that at the time this work was conducted, the negative 
enantiomer of L-Moses, D-45, reported in [36] was not commercially available; 
future studies should confirm the activity of L-Moses while using D-45 as a 
control. 
Future studies investigating the activity of L-Moses against Toxoplasma 
GCN5b bromodomain could address: determining the precise target of L-Moses 
in the parasite, evaluating the selectivity of the inhibitor for the Toxoplasma 
GCN5b bromodomain, and examining the in vivo effects of L-Moses.  
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As there are 12 putative bromodomain-containing proteins in Toxoplasma 
[24], L-Moses could potentially target other Toxoplasma bromodomains. 
Preliminary work using the established bromodomain binding assay suggests 
that L-Moses does not inhibit recombinant GCN5a bromodomain as efficiently as 
GCN5b bromodomain in vitro. Repeat experiments could validate this finding and 
future studies could test the effects of L-Moses on Toxoplasma GCN5a. The in 
vitro binding assay could also be utilized to determine the effects of L-Moses on 
other bromodomains, as well as to identify new small molecules that interfere 
with the GCN5b bromodomain. Moreover, to determine the precise target of L-
Moses in Toxoplasma, a forward genetics approach, as reported in Jeffers et al. 
[89], could be utilized. In this study, drug-resistant parasites were generated via 
chemical mutagenesis, followed by genome sequencing to identify mutations that 
confer drug resistance. 
Furthermore, resolving a crystal structure for the GCN5b bromodomain of 
Toxoplasma complexed with L-Moses would be helpful in determining key 
interactions between the bromodomain and inhibitor. Interestingly, three 
independent reports from groups testing PCAF/GCN5-specific bromodomain 
inhibitors have identified a common bromodomain/inhibitor interaction: a salt 
bridge between a conserved glutamate residue and the inhibitor. Humphreys et 
al. [66] identified the PCAF/GCN5-specific bromodomain inhibitor GSK4027. 
They performed crystallography on the human GCN5 bromodomain bound to 
GSK-4027 (PDB identification 5mlj) and identified a salt-bridge interaction 
between E761 (corresponding to E1389 in Plasmodium) and the inhibitor. 
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Moustakim et al. [36] reported the crystal structure of L-Moses bound to the 
GCN5 bromodomain from Plasmodium and identified a salt bridge between 
E1389 and the dimethylamino of L-Moses. Additionally, Chu et al. [62] performed 
a small molecule inhibitor screen of 42 compounds predicted to target the 
Plasmodium GCN5 bromodomain through canonical participation in hydrogen 
bond interaction with a conserved asparagine. Of the 42 compounds screened, 
the most active inhibitor was the only one to have a predicted salt-bridge 
between the morpholine nitrogen and E1389. The reported glutamate residue 
(corresponding to residue 1389 in Plasmodium and 761 in human GCN5) 
involved in the salt bridge interaction with bromodomain inhibitors is also 
conserved in Toxoplasma (E917 in Toxoplasma GCN5b). An analysis of 26 
crystal structures of human bromodomains complexed with histone tails revealed 
that a common interaction between bromodomains and histones is a salt bridge 
between the basic side chain of the histone tail and the acidic side chain of the 
bromodomain [90]. Ten of the 26 structures reviewed displayed the described 
salt bridge, and of these, the authors reported that three of the structures 
indicated that the salt bridge competes with the interaction between the histone 
tail and bromodomain, suggesting that the salt bridge interaction between the 
conserved glutamate residue and PCAF/GCN5-specific bromodomain inhibitors 
could be an interesting interaction to keep in mind when developing new 
inhibitors. 
With regards to testing the selectivity of L-Moses for the Toxoplasma 
GCN5b bromodomain, a potential approach could mirror one described in Kumar 
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et al. [43]. Kumar and colleagues used comparative sequence and structural 
analyses to determine differences in catalytic sites of the Plasmodium GCN5 
acetyltransferase domain compared to the human GCN5 acetyltransferase 
domain. Through virtual screening, this group identified known antimalarials and 
novel compounds with selectivity for PfGCN5 over HsGCN5. Given that the 
Toxoplasma GCN5b bromodomain shares a moderate degree of sequence 
identity (55%) (Table 1)(Figure 1A) and structural similarity (Figure 4) with the 
Plasmodium GCN5b bromodomain, it is likely that L-Moses will also show activity 
against Plasmodium and possibly other apicomplexan parasites. 
Future studies could investigate the effects of L-Moses, or a more specific, 
rationally-designed GCN5b bromodomain inhibitor in vivo. An outstanding 
question to address is the effects of L-Moses against tissue cysts, as GCN5a and 
GCN5b appear to play roles in bradyzoite development [45,26]. In vivo studies 
could address the effects of L-Moses on tachyzoite proliferation and tissue cyst 
elimination in mice.  
The data presented in this work suggests that the bromodomain of 
Toxoplasma GCN5b is a novel therapeutic target that is important for tachyzoite 
viability, and that the PCAF/GCN5 bromodomain inhibitor L-Moses is a lead 
compound against Toxoplasma.  
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